Spectrum of De Novo Cancers and Predictors in Liver Transplantation: Analysis of the Scientific Registry of Transplant Recipients Database.

PubWeight™: 0.78‹?›

🔗 View Article (PMID 27171501)

Published in PLoS One on May 12, 2016


Jie Zhou1,2, Zhenhua Hu1,2, Qijun Zhang1,2, Zhiwei Li1,2, Jie Xiang1,2, Sheng Yan1,2, Jian Wu1,2, Min Zhang1,2, Shusen Zheng1,2

Author Affiliations

1: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, Key Laboratory of Organ Transplantation, Hangzhou, Zhejiang, China.
2: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

Articles cited by this

Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet (2007) 11.06

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med (2002) 7.06

Cancer after kidney transplantation in the United States. Am J Transplant (2004) 5.08

Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99

Cancer incidence before and after kidney transplantation. JAMA (2006) 4.77

Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology (2011) 3.57

Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology (2010) 3.54

Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res (2013) 2.88

Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer (1995) 2.82

Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer (2003) 2.64

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation (2009) 2.33

Analytical methods and database design: implications for transplant researchers, 2005. Am J Transplant (2006) 2.14

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol (2006) 1.73

Cancer incidence among Canadian kidney transplant recipients. Am J Transplant (2007) 1.66

Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant (2010) 1.64

OPTN/SRTR 2011 Annual Data Report: liver. Am J Transplant (2013) 1.48

Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2010 data report. Am J Transplant (2011) 1.46

Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation (2004) 1.40

Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl (2001) 1.40

Solid-organ transplantation in older adults: current status and future research. Am J Transplant (2012) 1.33

De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl (2001) 1.30

Cancer incidence in a kidney-transplanted population. Transpl Int (2000) 1.25

mTOR, cancer and transplantation. Am J Transplant (2008) 1.24

Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant (2006) 1.20

Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology (2009) 1.18

Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy. Am J Transplant (2003) 1.13

Late mortality after orthotopic liver transplantation. Am J Surg (2001) 1.12

Tacrolimus for primary liver transplantation: 12 to 15 years actual follow-up with safety profile. Transplant Proc (2005) 0.98

Risk factors for development of de novo neoplasia after liver transplantation. Liver Transpl (2001) 0.98

Risk of Kaposi's sarcoma and of other cancers in Italian renal transplant patients. Br J Cancer (2005) 0.95

Non-lymphoid cancer after liver transplantation. Hepatogastroenterology (1997) 0.94

De novo tumors are a major cause of late mortality after orthotopic liver transplantation. Transplant Proc (2009) 0.88

Late mortality in 679 consecutive liver transplant recipients: the Gothenburg liver transplant experience. Transplant Proc (2006) 0.87

Malignancy following liver transplantation: a report from the Australian Combined Liver Transplant Registry. Transplant Proc (1995) 0.87

De novo cancer-related death in Australian liver and cardiothoracic transplant recipients. Am J Transplant (2013) 0.85

De novo cancers following liver transplantation: a single center experience in China. PLoS One (2014) 0.77